Welcome & Introduction

Newer Neo & Adjuvant treatment options in NSCLC

Recent Advances in Targeted therapy for metastatic Lung Cancer

Targeting EGFR Exon 19 & Exon 21

Unmet need in management of ALK positive metastatic NSCLC

New Advent for Atezolizumab in 1L

Moving the needle for mNSCLC management focusing on PDL1 negatives

IMpower 133 Tecentriq plus chemotherapy in 1L extensive stage Small Cell Lung Cancer

Closing Remarks